title: Anti-cancer actions of denosumab.
abstract: Denosumab works by binding to and inhibiting receptor activator of nuclear factor-κB ligand (RANKL). Through this mechanism, it can inhibit any cause of bone destruction and thus shows great efficacy in high-turnover osteoporosis. The FREEDOM (Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months) trial established the effectiveness of denosumab as a therapy for menopausal bone loss, whereas several newer trials have found denosumab to have shown denosumab to be beneficial in preventing skeletal events from bone metastases. This review highlights the potential novel anti-cancer mechanisms of action of denosumab in mammary tumors.
authors.affiliation: The Mount Sinai Bone Program, Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY 10029, USA.
authors.forename: Jameel
authors.initials: J
authors.lastname: Iqbal
authors.forename: Li
authors.initials: L
authors.lastname: Sun
authors.forename: Jeffrey I
authors.initials: JI
authors.lastname: Mechanick
authors.forename: Mone
authors.initials: M
authors.lastname: Zaidi
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000069448:Denosumab; D004195:Disease Models, Animal; D005260:Female; D006801:Humans; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy; D051379:Mice; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy; D053245:RANK Ligand / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D053245:RANK Ligand; D000069448:Denosumab